We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
- Authors
Piro, L D; White, C A; Grillo-López, A J; Janakiraman, N; Saven, A; Beck, T M; Varns, C; Shuey, S; Czuczman, M; Lynch, J W; Kolitz, J E; Jain, V
- Abstract
Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen which has been utilized for therapy of B-cell non-Hodgkin's lymphoma (NHL). A previous clinical trial demonstrated that treatment with four weekly doses of 375 mg/m2 of Rituximab in patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma was well tolerated and had significant clinical activity.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Vol 10, Issue 6, p655
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1023/a:1008389119525